de Vries Rory D, Rimmelzwaan Guus F
a Department of Viroscience , Erasmus MC , Rotterdam , The Netherlands.
Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901. doi: 10.1080/21645515.2016.1210729. Epub 2016 Jul 25.
Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.
季节性流感病毒的抗原漂移以及新型亚型流感病毒偶尔传入人群，使得及时生产出能在抗原上与引起流行或大流行疫情的病毒株相匹配的有效疫苗变得复杂。开发能诱导针对多种流感病毒产生广泛保护性免疫的突破性疫苗是一项尚未满足的需求，而重组病毒载体可能会有所帮助。使用病毒载体可将任何流感病毒抗原或其衍生物递送至免疫系统，从而最佳地诱导针对所选抗原的病毒特异性B细胞和T细胞反应。本系统综述讨论了载体流感病毒疫苗的研究结果以及目前可用病毒载体的优缺点。
